Journal Article

Visceral Leishmaniasis in Renal Transplant Recipients: Successful Treatment with Liposomal Amphotericin B (AmBisome)

John N. Boletis, Angelos Pefanis, Charalampos Stathakis, Helen Helioti, Apostolos Kostakis and Helen Giamarellou

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 28, issue 6, pages 1308-1309
Published in print June 1999 | ISSN: 1058-4838
Published online June 1999 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/514784
Visceral Leishmaniasis in Renal Transplant Recipients: Successful Treatment with Liposomal Amphotericin B (AmBisome)

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Visceral leishmaniasis (VL) is a rare disease in renal transplant recipients. Liposomal amphotericin B (AmBisome) is known to be effective against VL. However, previously there has been no experience with administration of such treatment to renal transplant recipients. We report herein four patients with VL complicating renal transplantation who were treated successfully with liposomal amphotericin B (total dose, 23–40 mg/kg). Neither adverse reactions nor clinical relapses of VL were observed.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.